These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25244504)

  • 1. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
    Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
    Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
    Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
    J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-γ nuclear export.
    Khateeb J; Kiyan Y; Aviram M; Tkachuk S; Dumler I; Fuhrman B
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):449-58. PubMed ID: 22155455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator (uPA) decreases hepatic SR-BI expression and impairs HDL-mediated reverse cholesterol transport.
    Chulsky S; Paland N; Lazarovich A; Fuhrman B
    Atherosclerosis; 2014 Mar; 233(1):11-8. PubMed ID: 24529115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1.
    König B; Koch A; Spielmann J; Hilgenfeld C; Hirche F; Stangl GI; Eder K
    Eur J Pharmacol; 2009 Mar; 605(1-3):23-30. PubMed ID: 19248225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
    Hsu WH; Chen CN; Huang HI; Lai YL; Teng CY; Kuo WH
    J Cell Physiol; 2012 Feb; 227(2):697-704. PubMed ID: 21465475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
    Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
    Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner.
    Fuhrman B; Nitzan O; Karry R; Volkova N; Dumler I; Aviram M
    Atherosclerosis; 2007 Dec; 195(2):e108-16. PubMed ID: 17681345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
    Fuhrman B; Khateeb J; Shiner M; Nitzan O; Karry R; Volkova N; Aviram M
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
    Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
    Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism.
    Song H; Zhu L; Picardo CM; Maguire G; Leung V; Connelly PW; Ng DS
    Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E17-E25. PubMed ID: 16105858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.
    Jin K; Norris K; Vaziri ND
    Nephrol Dial Transplant; 2013 Feb; 28(2):313-20. PubMed ID: 23045433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER.
    Rong S; Xia M; Vale G; Wang S; Kim CW; Li S; McDonald JG; Radhakrishnan A; Horton JD
    Cell Metab; 2024 Mar; 36(3):617-629.e7. PubMed ID: 38340721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.